Technology Listings


21 Results Sort By:
Targeting SREBP1 for Managing Acquired Resistance to Osimertinib/AZD9291 and Other EGFR Inhibitors for Non-small Cell Lung Cancer Treatment
­ Application Small molecule combination therapy (adjuvant, sensitizing agent) for Osimertinib (to treat non-small cell lung cancer with common EGFR activating mutations and T790M resistant mutation). Key Benefits Therapy against EGFR-TKI resistant tumors with mutant EGFR (e.g., T790M). Market Summary Non-small cell lung cancer (NSCLC)...
Published: 5/13/2022       Contributor(s): Shi-Yong Sun, Zhen Chen
IACS-0107059 for Sensitizing Resistant Multiple Myeloma (MM) for Venetoclax Therapy
­ Application Combinatorial drug therapy for resistant multiple myeloma. Key Benefits Clinically approved drugs to repurpose for multiple myeloma. Therapies for multiple myeloma that is resistant to other therapies. Market Summary Multiple myeloma (MM) is a plasma cell malignancy estimated to account for 12K deaths and 32K new diagnoses in...
Published: 3/16/2022       Contributor(s): Malathy (mala) Shanmugam, Aditi Sharma
A Predictive Marker and Treatment to Sensitize Multiple Myeloma Patients to Venetoclax (ABT-199)
Application A marker that predicts Venetoclax (ABT-199) sensitivity that can also be targeted with a drug to help multiple myeloma patients. Key Benefits Marker that predicts if venetoclax will be an effective treatment in multiple myeloma patients. A drug that targets venetoclax resistant multiple myeloma cells to improve treatment in patients. Market...
Published: 2/23/2022       Contributor(s): Malathy (mala) Shanmugam, Richa Bajpai
Repurposed Treatment for Cocaine Use Disorder
Application Repurposed drug for transcriptomic-driven treatment of cocaine use disorder. Key Benefits FDA-approved drug. Outperformed current targets undergoing clinical trials for CUD at the mRNA level. Market Summary In 2018, there were approximately 2.2 million regular users of cocaine in the United States, and 1 million individuals with...
Published: 1/23/2021       Contributor(s): Rohan Palmer, Spencer Huggett
Drug Combination to Treat Lung Cancer Metastasis
Application Combination product co-targeting PDH and GLUT1 to inhibit lung cancer metastasis. Key Benefits Combination of drugs exhibits greater synergism in cancer cell lines (H1299, 4T1, H1792). Has potential to prevent metastasis in a variety of cancers. Decreases both cell viability and invasive area. Repurposed drugs. Market Summary Lung...
Published: 10/1/2020       Contributor(s): Malathy (mala) Shanmugam, Adam Marcus
HDAC Inhibitors for Managing Vascular Conditions and Diabetic Peripheral Neuropathies
Application Treatment of diabetic neuropathy using epigenetic modulators, histone deacetylase inhibitors (HDACis), to ameliorate or prevent vascular conditions and neuropathic pains by nerve damages. Key Benefits Reverses or protects against diabetes-induced nerve damages by direct injection of HDACi. Relatively low regulatory risk because many...
Published: 4/24/2020       Contributor(s): Young-Sup Yoon, Ji Woong (Jay) Han, Hyunsuk Shim
Therapeutic Compounds Inhibiting DUSP5 and DUSP6 for Cardiomyocyte Proliferation and Cardiac Regeneration
Application Therapeutics using siRNAs and small molecules to treat congenital heart defect and myocardial injuries. Key Benefits Reactivates cardiomyocyte (CM) cell replication, allowing regeneration of heart muscle after cardiac injuries. Therapeutic compounds may be administered for transient regeneration/repair of heart muscle after cardiac...
Published: 4/22/2020       Contributor(s): Ahsan Husain, Nawazish Naqvi
Combination Therapy to Treat Pediatric Brain Tumor
Application Combination therapy (inhibition of STAT3 and YB-1) to treat medulloblastoma. Key Benefits Drug combination targets cancer stem cells. Increased apoptosis of cancer cells compared to current chemotherapeutic agents. Market Summary Medulloblastoma (MB) is the most common cancerous brain tumor that affects children and survival rates...
Published: 1/28/2020       Contributor(s): Tobey MacDonald, Anna Kenney, James Felker, Abhinav Dey
Small Molecules to Promote Bone Growth
Application Small molecule sclerostin-inhibitors to enhance the canonical Wnt pathways and promote BMP-induced osteoblast differentiation. Key Benefits Repurposing opportunities of FDA approved drugs. Lower cost compared to currently available monoclonal antibody or recombinant protein therapies. Stable compounds with established safety profiles...
Published: 12/3/2019       Contributor(s): Scott Boden, Steven Presciutti, Sreedhara Sangadala
Targeted Anti-Cancer Nanoparticle Therapy
Application A drug-carrying nanoparticle that selectively targets cancer cells. Key Benefits Incorporates an already proven anti-cancer therapeutic. Increases deliverability. Targets cancer cells. Market Summary Tris DBA palladium has been shown to have anti-cancer activity against melanoma and pancreatic cancer. However, Tris DBA has not...
Published: 9/9/2019       Contributor(s): Jack Arbiser, Lily Yang
1 2 3